文献速递免疫规划传染病防控与疫情报告

既往感染并接种一剂疫苗者与未感染并接种三剂疫苗者对SARS-CoV2的细胞与体液免疫应答比较:病例对照研究

Cellular and humoral immune responses to SARS-CoV2, comparing previously infected individuals who received one vaccine dose to uninfected individuals after three vaccine doses: A case-control study.
PubMed 文献 · Vaccine · 2025-07-23

该病例对照研究比较了既往感染SARS-CoV2后接种一剂BNT162b2 mRNA疫苗的健康康复者与未感染并接种三剂BNT162b2 mRNA疫苗者的体液和细胞免疫应答。结果显示两组供者样本结合RBD或抑制ACE2:RBD相互作用的能力相当,不因测试的变异株而异;但康复者在WT-S肽混合刺激后IFNγ染色增加(平均988.4 ± 687.1 vs 590.2 ± 397.1,p=0.022,每10^6 CD4+细胞中应答IFNγ+细胞数),对M蛋白肽混合的应答更强(平均2291 ± 4074.2 vs 239 ± 485.85,p=0.023)。

要点

  • 既往感染并接种一剂疫苗者与未感染并接种三剂疫苗者结合RBD或抑制ACE2:RBD的能力相当
  • 康复者WT-S肽刺激后IFNγ+细胞平均988.4 ± 687.1 vs 590.2 ± 397.1(p=0.022)
  • 康复者M蛋白肽刺激后IFNγ+细胞平均2291 ± 4074.2 vs 239 ± 485.85(p=0.023)

核心结论

  • 既往感染并接种一剂疫苗者结合RBD或抑制ACE2:RBD相互作用的能力与接种三剂疫苗的未感染者相当,不因测试的变异株而异。
  • 康复者经WT-S肽或M蛋白肽刺激后IFNγ染色较接种三剂疫苗的未感染者增加。

研究设计与样本

  • 病例对照研究,比较既往感染SARS-CoV2后接种一剂BNT162b2 mRNA疫苗的健康康复者与未感染并接种三剂BNT162b2 mRNA疫苗者。
  • 体液免疫通过供者样本结合或抑制不同SARS-CoV2变异株Spike糖蛋白受体结合域(RBD)与ACE2结合的能力评估。
  • 细胞免疫通过流式细胞术评估对Wuhan野生型(WT)Spike糖蛋白(S)肽混合、Omicron特异性S肽混合及膜(M)蛋白肽混合刺激的细胞因子产生。

主要发现

  • 康复者单剂接种者结合RBD或抑制ACE2:RBD相互作用的能力与三剂接种的未感染者相当,不因测试的变异株而异。
  • WT-S肽混合刺激后,康复者IFNγ染色平均为988.4 ± 687.1 vs 未感染者590.2 ± 397.1(p=0.022,每10^6 CD4+细胞中应答IFNγ+细胞数)。
  • M蛋白肽混合刺激后,康复者IFNγ染色平均为2291 ± 4074.2 vs 未感染者239 ± 485.85(p=0.023,每10^6 CD4+细胞中应答IFNγ+细胞数)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the last 5 years, the world has been facing the Corona Virus Disease 2019 (COVID-19) pandemic caused by the SARS-CoV2 virus. While vaccination is a leading strategy to control virus spread, it demonstrated an ability to push the virus to evolve and generate vaccine-escape variants. Nevertheless, the official policy in Israel and around the world is vaccination, even in cases of previous SARS-CoV2 infection. Many studies were published regarding vaccination protocols and antibody responses. However, data concerning the differences in humoral and cellular immune response between convalescent individuals who received a single vaccine dose, and SARS-CoV2 naïve vaccinated individuals, are still sparse. In this study we evaluated the humoral and cellular immune response of healthy convalescent individuals who received a single vaccine dose, and compared it with uninfected individuals who received three BNT162b2 mRNA vaccine doses. Humoral immune response was evaluated by testing the ability of donor samples to bind or inhibit the binding of different SARS-CoV2 variants Spike glycoprotein receptor binding domain (RBD) to ACE2. Cellular immunity was tested using flow cytometry to evaluate cytokine production in response to different SARS-CoV2 peptide mixes, including the Wuhan wild-type (WT) Spike glycoprotein (S)-peptide mix, Omicron-specific S-peptide mix and the Membrane (M) protein peptide mix. We show that the ability of convalescent, single-dose vaccinated, donors to bind RBD or inhibit ACE2:RBD interaction was comparable to that of 3-dose vaccinated-only donors, independent of the variant tested. In contrast, when testing cellular response, convalescent individuals showed increased IFNγ staining following WT-S peptide mix stimulation (average of 988.4 ± 687.1 vs 590.2 ± 397.1, p = 0.022 responding IFNγ+ cells per 106 CD4+ cells), and even more enhanced response to M-protein peptide mix (average of 2291 ± 4074.2 vs 239 ± 485.85, p = 0.023 responding IFNγ+ cells per 106 CD4+ cells). This research may provide information for future development of more effective vaccines and vaccination strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Saiag E, Shalit R, Alcalay Y, et al. Cellular and humoral immune responses to SARS-CoV2, comparing previously infected individuals who received one vaccine dose to uninfected individuals after three vaccine doses: A case-control study. Vaccine. 2025. PMID: 40706511. doi:10.1016/j.vaccine.2025.127525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。